 |
|
A Case of Idiopathic Central Serous Chorioretinopathy in a 12-year-old Male Treated with Bevacizumab
Yu Cheol Kim, Si Dong Kim, Kwang Soo Kim
Korean J Ophthalmol. 2012;26(5):391-393. Published online 2012 Sep 24 DOI: https://doi.org/10.3341/kjo.2012.26.5.391
|
|
Citations to this article as recorded by
 Diagnostic and Therapeutic Challengess
Prithvi Ramtohul, K. Bailey Freund, Won Ki Lee
Retina.2021; 41(8): 1786. CrossRef Diagnostic and Therapeutic Challenges
Sarra Gattoussi, K. Bailey Freund, Michael J. Heiferman, Amani A. Fawzi
Retina.2018; 38(9): 1876. CrossRef A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®)
Erdem Eris, Gurkan Erdogan, Irfan Perente, Gokhan Demir, Burcin Kepez Yildiz, Ebru Demet Aygit
Case Reports in Ophthalmological Medicine.2017; 2017: 1. CrossRef RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY
Bing Liu, Tuo Deng, Junjun Zhang
Retina.2016; 36(1): 9. CrossRef Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis
Alejandra Daruich, Alexandre Matet, Ali Dirani, Elodie Bousquet, Min Zhao, Nicolette Farman, Frédéric Jaisser, Francine Behar-Cohen
Progress in Retinal and Eye Research.2015; 48: 82. CrossRef Bevacizumab in age-related macular degeneration – comparison of subjective estimation of vision with objective test results
Anna Piotrowska-Gwóźdź, Agnieszka Piotrowska-Seweryn, Grażyna Mazur-Piotrowska
Annales Academiae Medicae Silesiensis.2015; 69: 33. CrossRef Polymer microneedles for transdermal drug delivery
Jeong Woo Lee, Mee-Ree Han, Jung-Hwan Park
Journal of Drug Targeting.2013; 21(3): 211. CrossRef
|